Zemaira®

Understanding Zemaira®

Zemaira® is used to treat Alpha-1 Antitrypsin Deficiency (AATD) in adults with emphysema caused by AATD. Zemaira® provides functional alpha-1 antitrypsin (AAT) to the lungs, helping to prevent lung tissue destruction by blocking neutrophil elastase—an enzyme that damages lung tissue in AATD patients. This chronic augmentation therapy is designed to help preserve lung function and improve quality of life.

How Zemaira® Works:

• Provides functional AAT to help protect lung tissue
• Blocks neutrophil elastase, preventing lung damage
• Slows disease progression in AATD-related emphysema

FDA Approval:

• Zemaira®: Approved in July 2003 for Chronic Augmentation Therapy in AATD-related emphysema.

For more information, please visit the Zemaira® patient website and speak with your healthcare provider to determine if Zemaira® is the right treatment option for you.